Business
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p Patients in the RADIANT study of vormatrigine
About this update from Praxis Precision Medicines, Inc.
[{"type":"text","content":"Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p Patients in the RADIANT study of vormatrigine showed rapid, consistent and durable improvement in seizure reduction, reaching 100% for patients continuing through 16 weeks Expansion of the Praxis Analysis of Concordance Framework to include DEEs Showcase of the most comprehensive epilepsy portfolio BOSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided clinical updates shared at the American Epilepsy Society Annual Meeting (AES) on December 6, 2025. “The updates we shared at AES mark a pivotal moment for epilepsy treatment. The EMBOLD results highlight the long-awaited potential of relutrigine to become the first disease modifying treatment for SCN2A and SCN8A-DEE patients and show that we are positioned to deliver the same impact for the broader DEE community,” said Marcio Souza, president and chief executive officer. “Additionally, the update from the RADIANT study for focal-onset seizures and generalized epilepsy confirmed its potential as a best-in-class therapy. We are committed to accelerating these options to patients while continuing to accelerate the broad DEE study, EMERALD, our ASO programs and the FOS studies toward registration.” Relutrigine for Developmental and Epileptic Encephalopathies (DEEs): At AES, Praxis shared results [link to poster] of the EMBOLD study, demonstrating relutrigine was well-tolerated with rapid, significant and increasing seizure reduction over time with broad functional improvements across behavior, alertness, communication and overall status. Praxis will meet with the FDA in the coming weeks to discuss next steps for the New Drug Application (NDA). Praxis will make a determination of the timing for filing the NDA after the meeting. Patients receiving relutrigine (n=51) experienced a 53% placebo-adjusted reduction in seizures over 16-weeks (p","length":3303,"tagName":"div"}]